Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -116.14% is 60% above its 3-year average of -292.69%, near the high end of its 3-year range (-611.87%–-90.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.65% below its 12-month average of -103.10%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -116.14%.
RETURN ON EQUITY (ROE)
-116.14%
RETURN ON EQUITY (ROE) AVG TTM
-103.10%
RETURN ON EQUITY (ROE) AVG 3Y
-292.69%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-12.65%
CURRENT VS 3Y AVG
+60.32%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-176.46%
vs the sector median at left
MIRA Pharmaceuticals, Inc.
Market Cap
$29.91M
Return on Equity (ROE)
-116.14%
TTM Avg
-103.10%
3Y Avg
-292.69%
5Y Avg
N/A
Market Cap
$29.74M
Return on Equity (ROE)
-111.81%
TTM Avg
-29.10%
3Y Avg
-257.52%
5Y Avg
159.26%
Market Cap
$30.19M
Return on Equity (ROE)
-14.49%
TTM Avg
-7.92%
3Y Avg
-46.98%
5Y Avg
-261.20%
Market Cap
$29.57M
Return on Equity (ROE)
-120.40%
TTM Avg
-43.89%
3Y Avg
-83.08%
5Y Avg
-65.54%
Market Cap
$30.44M
Return on Equity (ROE)
-15.29%
TTM Avg
-28.05%
3Y Avg
-476.74%
5Y Avg
-371.52%
Market Cap
$29.37M
Return on Equity (ROE)
-117.69%
TTM Avg
-1443.79%
3Y Avg
-971.02%
5Y Avg
-813.57%
Market Cap
$30.81M
Return on Equity (ROE)
N/A
TTM Avg
10.32%
3Y Avg
-262.53%
5Y Avg
-267.00%
Market Cap
$30.92M
Return on Equity (ROE)
-132.18%
TTM Avg
-94.77%
3Y Avg
-38.62%
5Y Avg
-46.78%
Market Cap
$31.11M
Return on Equity (ROE)
-117.97%
TTM Avg
-59.96%
3Y Avg
-42.92%
5Y Avg
-31.82%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MIRA Pharmaceuticals, Inc. (MIRA) | $29.91M | -116.14% | -103.10% | -292.69% | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.74M | -111.81% | -29.10% | -257.52% | 159.26% |
| Rockwell Medical, Inc. (RMTI)vs › | $30.19M | -14.49% | -7.92% | -46.98% | -261.20% |
| Context Therapeutics Inc. (CNTX)vs › | $29.57M | -120.40% | -43.89% | -83.08% | -65.54% |
| SCYNEXIS, Inc. (SCYX)vs › | $30.44M | -15.29% | -28.05% | -476.74% | -371.52% |
| Quantum Cyber N.V. (QUCY)vs › | $29.37M | -117.69% | -1443.79% | -971.02% | -813.57% |
| MDxHealth S.A. (MDXH)vs › | $30.81M | N/A | 10.32% | -262.53% | -267.00% |
| CervoMed Inc. (CRVO)vs › | $30.92M | -132.18% | -94.77% | -38.62% | -46.78% |
| Accuray Incorporated (ARAY)vs › | $31.11M | -117.97% | -59.96% | -42.92% | -31.82% |
| BeyondSpring Inc. (BYSI)vs › | $28.47M | N/A | 29.33% | 173.42% | 64.03% |
ROE
-116.1%
ROA
-115.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -116.14% |
| 2026-03-31 | -104.92% |
| 2025-12-31 | -100.49% |
| 2025-09-30 | -90.85% |
| 2025-03-31 | -611.87% |
| 2024-12-31 | -356.98% |
| 2024-09-30 | -314.53% |
| 2024-06-30 | -576.14% |
| 2024-03-31 | -391.51% |
| 2023-12-31 | -273.92% |
| 2023-09-30 | -92.97% |
| 2023-06-30 | -481.97% |
